IN8bio, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for INAB, updated each market day.
INAB AI Sentiment
AI sees no strong directional signal for IN8bio, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About IN8bio, Inc. Common Stock
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Sector
Exchange
Market Cap
$14,081,337
Cap Tier
Employees
17
Headquarters
NEW YORK, NY
Listed Since
July 30, 2021
Website
INAB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
INAB Volatility
IN8bio, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
